Blood Pressure Lowering Effects of Amosartan Regarding Proviso iN Patients With High Blood Pressure
1 other identifier
observational
50
0 countries
N/A
Brief Summary
Blood Pressure Lowering Effects of Amosartan Regarding Proviso in Patients with Hypertension
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jan 2014
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2015
CompletedFirst Submitted
Initial submission to the registry
August 16, 2017
CompletedFirst Posted
Study publicly available on registry
August 21, 2017
CompletedAugust 21, 2017
August 1, 2017
1.5 years
August 16, 2017
August 16, 2017
Conditions
Outcome Measures
Primary Outcomes (1)
Patients with essential hypertension evaluated the mean blood pressure after taking amosartan.
Blood Pressure Lowering Effects of Amosartan Regarding Proviso in Patients with Hypertension
6 month
Interventions
amosartan is a combination of amlodipine, which is a calcium channel blocker (CCB), and rozatan, an angiotensin II receptor antagonist (ARB), and is an antihypertensive agent
Eligibility Criteria
Estimated total number of patients: 3,150 Estimated number of centers: 37
You may qualify if:
- Patients with essential hypertension whose blood pressure is not adequately controlled by amlodipine or rosartan monotherapy
- In patients with stage 2 hypertension (SBP 160-179 mmHg), patients requiring a combination therapy to reach the target blood pressure
- Patients who were changed to amosartan while using other hypertensive agents
You may not qualify if:
- Patients with hypersensitivity to dihydropyridine derivatives of amosartan
- Women who are pregnant or who may be pregnant and breastfeeding
- Patients with severe hepatic dysfunction
- Patients with severe aortic stenosis
- Patients at risk of shock
- Patients participating in other clinical studies
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (3)
Kim SH, Ryu KH, Lee NH, Kang JH, Kim WS, Park SW, Lee HY, Kim JJ, Ahn YK, Suh SY. Efficacy of fixed-dose amlodipine and losartan combination compared with amlodipine monotherapy in stage 2 hypertension: a randomized, double blind, multicenter study. BMC Res Notes. 2011 Oct 28;4:461. doi: 10.1186/1756-0500-4-461.
PMID: 22035131BACKGROUNDLaw MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003 Jun 28;326(7404):1427. doi: 10.1136/bmj.326.7404.1427.
PMID: 12829555BACKGROUNDChoi SM, Seo MJ, Kang KK, Kim JH, Ahn BO, Yoo M. Beneficial effects of the combination of amlodipine and losartan for lowering blood pressure in spontaneously hypertensive rats. Arch Pharm Res. 2009 Mar;32(3):353-8. doi: 10.1007/s12272-009-1307-x. Epub 2009 Apr 23.
PMID: 19387578BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Seoul National University Bundang Hospital
Study Record Dates
First Submitted
August 16, 2017
First Posted
August 21, 2017
Study Start
January 1, 2014
Primary Completion
June 30, 2015
Study Completion
December 31, 2015
Last Updated
August 21, 2017
Record last verified: 2017-08
Data Sharing
- IPD Sharing
- Will not share